7/18/2019 · In after-hours, the stock was down 8.31% to $19.32. DURECT Corporation's (DRRX) full response to the Complete Response Letter it previously received from FDA related to POSIMIR (bupivacaine extended-release solution) has been accepted by the regulatory agency, and a decision is expected on December 27, 2019. 02 October 2019 DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain. CUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR®

7/18/2019 · In after-hours, the stock was down 8.31% to $19.32. DURECT Corporation's (DRRX) full response to the Complete Response Letter it previously received from FDA related to POSIMIR (bupivacaine extended-release solution) has been accepted by the regulatory agency, and a decision is expected on December 27, 2019. 02 October 2019 DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain. CUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR® 12/16/2019 · GAINESVILLE, Florida, 16 de diciembre de 2019 /PRNewswire/ -- etectRx ®, Inc. (etectRx), una compañía privada de salud digital, ha anunciado la aprobación por parte de la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) de su nuevo e innovador sensor ingerible patentado, el sistema ID-Cap ®. 6/28/2019 · Further, DRRX’s CRL response includes substantive additional data that supports safety of the drug. FDA’s response is anticipated within six months – which means we may not hear back until sometime near year-end. As we had removed POSIMIR from our model, a favorable response from FDA would likely provide upside to our estimates. 12/3/2019 · Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection Durect Corp.'s (DRRX) licensee Pain Therapeutics (PTIE) new drug application for an opioid analgesic was denied by the FDA. Annie Palmer For the last week, the stock has had a daily average volatility of 13.52%. The stock is extremely overbought on RSI14 (97). Normally this may pose a good selling opportunity but since the stock has broken the trend up, the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken. Real-time trade and investing ideas on Durect Corp. DRRX from the largest community of traders and investors. Rooms Trade App. More. ©2019 StockTwits, Inc.

12/30/2019 · DRRX closed up 8.28 percent on Monday, December 30, 2019, on 3.82 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Durect Corp. company facts, information and stock details by MarketWatch. View drrx business summary and other industry information. 12/31/2019 · DURECT (NASDAQ:DRRX) is up 4% premarket on light volume, potentially adding to its 88% rally since December 16. Investors appear to be expecting good news from the FDA's review of the company's responses to the CRL it received in February 2014 related to its marketing application for pain med Posimir (bupivacaine) citing the need for more safety data. Check out our DRRX stock analysis, current DRRX quote, charts, and historical prices for Durect Corp stock. Agile Awaits FDA Verdict 12/30/2019 · DRRX closed up 8.28 percent on Monday, December 30, 2019, on 3.82 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought. DURECT Corp (DRRX) Announces FDA Approval of Indivior's PERSERIS Extended-Release Injectable Suspension for Treatment of Schizophrenia in Adults Article Related Press Releases ( 1 ) Stock Quotes (2) Comments (0) Close price at the end of the last trading day (Friday, 20th Dec 2019) of the DRRX stock was $2.41. This is 6.64% more than the trading day before Thursday, 19th Dec 2019. During the day the stock fluctuated 6.88% from a day low at $2.26 to a day high of $2.42.

In after-hours, the stock was down 8.31% to $19.32. DURECT Corporation's full response to the Complete Response Letter it previously received from FDA related to POSIMIR (bupivacaine extended-release solution) has been accepted by the regulatory agency, and a decision is expected on December 27, 2019.

Find the latest DURECT Corporation (DRRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Real-time trade and investing ideas on Durect Corp. DRRX from the largest community of traders and investors. Rooms Trade App. More. ©2019 StockTwits, Inc.

12/16/2019 · GAINESVILLE, Florida, 16 de diciembre de 2019 /PRNewswire/ -- etectRx ®, Inc. (etectRx), una compañía privada de salud digital, ha anunciado la aprobación por parte de la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) de su nuevo e innovador sensor ingerible patentado, el sistema ID-Cap ®. 6/28/2019 · Further, DRRX’s CRL response includes substantive additional data that supports safety of the drug. FDA’s response is anticipated within six months – which means we may not hear back until sometime near year-end. As we had removed POSIMIR from our model, a favorable response from FDA would likely provide upside to our estimates.

Check out our DRRX stock analysis, current DRRX quote, charts, and historical prices for Durect Corp stock. Agile Awaits FDA Verdict

Hace 1 día · DURECT Corporation (NASDAQ: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928 topically to the plaque on one arm and the vehicle (placebo) to a similar plaque on the other arm daily for 28 days. DRRX: Get the latest Durect stock price and detailed information including DRRX news, historical charts and realtime prices. Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content. CUPERTINO - DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Stifel 2019 Health Care Conference, at the Lotte New York Palace Hotel on Tuesday, November 19, 2019 at 3:35 p.m. EST. Charts, forecasts and trading ideas from trader JuanDeZubiriaRago. Get unique market insights from the largest community of active traders and investors. 8/2/2016 · DRRX may be well positioned to obtain approval this time around. FDA decisions can make or break developmental-stage pharmaceutical companies. With millions of dollars invested in the development of a drug, an FDA decision represents the culmination of years of hard work and millions of dollars

6/28/2019 · Further, DRRX’s CRL response includes substantive additional data that supports safety of the drug. FDA’s response is anticipated within six months – which means we may not hear back until sometime near year-end. As we had removed POSIMIR from our model, a favorable response from FDA would likely provide upside to our estimates. 12/3/2019 · Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection Durect Corp.'s (DRRX) licensee Pain Therapeutics (PTIE) new drug application for an opioid analgesic was denied by the FDA. Annie Palmer